Jacobson Pharma

Jacobson Pharma, a company engaged in Pharmaceutical Preparation Manufacturing with its headquarters in Hong Kong, reported a total of approximately 32.1 million kg CO2e in Scope 1 and Scope 2 emissions in 2026. This figure is based on market-based accounting and comprises approximately 1.25 million kg CO2e from Scope 1 emissions and approximately 21.83 million kg CO2e from Scope 2 emissions. In the same year, Scope 3 emissions were approximately 32.09 million kg CO2e, with purchased goods and services accounting for the largest portion at approximately 31.38 million kg CO2e.

For the financial year 2025, Jacobson Pharma's Scope 1 and Scope 2 emissions, calculated using market-based methods, amounted to approximately 20.84 million kg CO2e. Scope 1 emissions were approximately 1.20 million kg CO2e, and Scope 2 emissions were approximately 19.65 million kg CO2e.

In 2024, the company's total emissions were approximately 16.94 million kg CO2e. This included Scope 1 emissions of approximately 1.19 million kg CO2e, Scope 2 emissions of approximately 15.50 million kg CO2e (market-based), and Scope 3 emissions of approximately 249,020 kg CO2e.

Looking at earlier reporting years, Jacobson Pharma reported total emissions of approximately 63.22 million kg CO2e in 2023, with Scope 1 emissions at approximately 39.45 million kg CO2e and Scope 2 emissions at approximately 23.61 million kg CO2e. In 2022, total emissions were approximately 60.33 million kg CO2e, comprising approximately 37.25 million kg CO2e in Scope 1 and approximately 23.11 million kg CO2e in Scope 2. For 2021, total emissions were approximately 53.28 million kg CO2e, with Scope 1 at approximately 34.40 million kg CO2e and Scope 2 at approximately 18.75 million kg CO2e.

Jacobson Pharma has set a near-term reduction target to decrease electricity usage intensity by revenue by 3% by FY2026, compared to a FY2020 baseline. This initiative aims to reduce electricity usage intensity by revenue by 3% of all facilities.